Prevail Therapeutics

This early-stage study tests a single intravenous dose of a gene therapy called LY3884961 in 15 adults with Gaucher disease type 1. The goal is to see if it is safe and can reduce or replace the need for ongoing enzyme replacement or substrate reduction therapy. Participants must…

This early-stage study tests a new drug called LY3962681 in healthy volunteers and people with Parkinson's disease. The goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo injected into the spinal fluid, and are fo…